Non-small cell lung cancer recurrent

14 trials 3 recruiting MedDRA PT
14 Registered trials
3 Recruiting
12 Unique sponsors
20 Unique IMPs
13 Commercial trials
Drug classes (ATC)
— ATC code not specified 8
L Oncology (ATC L) 5
N Neurology/Psychiatry (ATC N) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 9 substances
Kinase inhibitor 4 substances
Checkpoint inhibitor (PD-1) 2 substances
Platinum compound 2 substances
Checkpoint inhibitor (CTLA-4) 1 substance
Antimetabolite 1 substance
Checkpoint inhibitor (PD-L1) 1 substance
Phase III: 1 Phase II/III: 1 Phase II: 6 Phase I/II: 3 Phase I: 1 Phase I (Other): 1 Phase I (First in Human): 1

Filter these 14 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 14 trials

Phase III

1 trial
  • Xcovery Holding Co. LLC Commercial
    CRIZOTINIB; X-396
    2024-513454-29-00 7 countries 2015 n=47
    Ended

Phase II/III

1 trial
  • Bristol-Myers Squibb Services Unlimited Company Commercial
    2-[4-[4-(AMINOMETHYL)-1-OXO-2H-PHTHALAZIN-6-YL]-2-METHYLPYRAZOL-3-YL]-4-CHLORO-6-CYCLOPROPYLOXY-3-FLUOROBENZONITRILE
    2025-521511-40-00 15 countries 2025 n=191
    Recruiting

Phase II

6 trials
  • Anheart Therapeutics Inc. Commercial
    TALETRECTINIB
    2024-516604-41-00 4 countries 2022 n=98
    Ended
  • AstraZeneca AB Commercial
    OSIMERTINIB; SAVOLITINIB
    2024-512581-34-00 1 country 2019 n=76
    Ended
  • Bristol-Myers Squibb Services Unlimited Company Commercial
    BMS-986315; NIVOLUMAB
    2022-503007-22-00 5 countries n=95
    Ended
  • Bristol-Myers Squibb Services Unlimited Company Commercial
    IPILIMUMAB; NIVOLUMAB
    2024-520108-25-00 5 countries 2025 n=40
    Ended
  • Celgene Corp. Commercial
    AZACITIDINE
    2024-513405-31-00 1 country 2015 n=1
    Ended
  • Centre Francois Baclesse Academic
    ATEZOLIZUMAB; CARBOPLATIN; CISPLATIN
    2024-516201-23-00 1 country 2019 n=150
    Ended

Phase I/II

3 trials
  • BioNTech SE Commercial
    BNT326; BNT327
    2024-519344-32-00 4 countries 2026 n=88
    Recruiting
  • Cullinan Pearl Corp. Commercial
    CLN-081
    2024-516532-97-00 3 countries 2020 n=63
    Ended
  • Incyte Corp. Commercial
    ADAGRASIB; INCB099280
    2023-503223-26-00 3 countries 2024 n=75
    Ended

Phase I

1 trial
  • AbbVie Deutschland GmbH & Co. KG Commercial
    IMP not specified
    2024-513625-23-00 1 country 2021 n=1
    Ended

Phase I (Other)

1 trial
  • Systimmune Inc. Commercial
    IMP not specified
    2023-506539-14-00 3 countries 2025 n=95
    Recruiting

Phase I (First in Human)

1 trial
  • Achilles Therapeutics UK Limited Commercial
    ATL001; PEMBROLIZUMAB
    2024-513060-26-00 3 countries 2021 n=24
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Bristol-Myers Squibb Services Unlimited Company Commercial 3 Phase II/III, Phase II 1
AbbVie Deutschland GmbH & Co. KG Commercial 1 Phase I 0
Systimmune Inc. Commercial 1 Phase I (Other) 1
Anheart Therapeutics Inc. Commercial 1 Phase II 0
AstraZeneca AB Commercial 1 Phase II 0
Celgene Corp. Commercial 1 Phase II 0
Xcovery Holding Co. LLC Commercial 1 Phase III 0
Achilles Therapeutics UK Limited Commercial 1 Phase I (First in Human) 0
BioNTech SE Commercial 1 Phase I/II 1
Cullinan Pearl Corp. Commercial 1 Phase I/II 0
Incyte Corp. Commercial 1 Phase I/II 0
Centre Francois Baclesse Academic 1 Phase II 0
New trials by year
2019
2
2020
1
2021
2
2022
1
2024
1
2025
3
2026
1
← All indication landscapes